Skip to main content


Targeted Oncology

Targeted Oncology OnlineFirst articles

16.06.2018 | Therapy in Practice

BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review

The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib (AZD9291) has shown significant clinical efficacy against the EGFR T790M mutation in non-small cell lung cancer (NSCLC) patients. However …

14.06.2018 | Original Research Article

Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)

Bevacizumab is a humanized monoclonal antibody that binds vascular endothelial growth factor (VEGF), thereby preventing the activation of its receptor (VEGFR) and reducing tumor neoangiogenesis, a known hallmark of cancer [ 1 ]. Within the context …

07.06.2018 | Original Research Article Open Access

Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis

Pancreatic ductal adenocarcinoma (PDA) is the third leading cause of cancer-related deaths in the United States. In 2015, an estimated 48,960 new cases were diagnosed, which resulted in 40,000 deaths [ 1 ]. Despite improved knowledge regarding the …

17.04.2018 | Review Article

The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma

Malignant melanoma is the most aggressive and notorious skin cancer, and metastatic disease is associated with very poor long-term survival outcomes. Although metastatic melanoma patients with oncogenic mutations in the BRAF gene initially respond …

Aktuelle Ausgaben

Weitere Informationen

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.